Eisai Co. Ltd.

In News

Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation - Eisai Co., Ltd.

Eisai Co., Ltd. - Mar 17, 2026

Eisai Announces Strategic Investment Supported by the UK Government's LSIMF - JCN Newswire

JCN Newswire - Jun 17, 2026

Eisai Co., Ltd. (ESAIY) Analyst/Investor Day - Slideshow (OTCMKTS:ESAIY) 2026-05-25 - Seeking Alpha

Seeking Alpha - May 25, 2026

We’re teaming up with Eisai to help fight cancer - Merck.com

Merck.com - Mar 12, 2026

Eisai strikes Japan licensing deal with Shanghai Henlius Biotech - Reuters

Reuters - Feb 05, 2026

Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - PR Newswire

PR Newswire - Nov 25, 2025

Eisai Co Ltd Receives Orphan Drug Designation In Japan For Novel Orexin 2 Receptor Agonist E2086 - BioPharma APAC

BioPharma APAC - Feb 17, 2026

Eisai to expand UK manufacturing with government support - Investing.com

Investing.com - Jun 17, 2026

Audit Review Item 26/03: Eisai – Goodwill Valuation (Americas Pharmaceutical Business) - Moomoo

Moomoo - Jun 12, 2026

CD73-targeting immunoconjugates disclosed in Eisai patent - BioWorld News

BioWorld News - Mar 16, 2026

Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting - PR Newswire

PR Newswire - Mar 10, 2026

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan - Biogen

Biogen - Nov 27, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment